IDMC recommends to continue patient enrolment in Ph 1 ZIMA-101 trial in solid tumor patients August 25, 2026
Akiram Therapeutics and ITM Sign Lutetium-177 Supply Agreement to Support Development of AKIR001 for the Treatment of Solid Tumors August 25, 2026
FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors August 25, 2026
FDA clears IND application to proceed to Ph 1/2 clinical trial for XTX501 in solid tumors August 20, 2026
Tikva Allocell Secures $8 Million Series A Financing to Advance Engineered Off-the-Shelf Cell Therapies for Solid Tumors July 28, 2026
Lupin spins out two oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1) into Kaveri Therapeutics July 28, 2026
BeOne Medicines Expands U.S. Manufacturing with More Than $1 Billion Investment to Advance Cancer Medicines July 28, 2026
Enrollment completed in Ph 1 Dose Escalation Study of IPH4502 in patients with advanced solid tumors July 28, 2026
Confirmed Durable Partial Response in Ph 1 Trial of RAD204 in Patients with Advanced Solid Tumors Post-Immunotherapy July 28, 2026
First Patient Dosed in Ph 1 Trial of IM-3050 in Patients with FAP-Expressing Advanced Solid Tumors July 22, 2026
Ph 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors published in the JCO July 21, 2026
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors July 21, 2026
Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development July 15, 2026
FDA Accepts NDA for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma; PDUFA: May 2027 July 15, 2026
Updated Preliminary Ph 1 Data and Registration-Enabling Plans for ERAS-0015 in KRAS-Mutant Solid Tumors Announced July 15, 2026
FDA Clears IND Application for LTZ-232 to Treat Advanced Metastatic CRC and Other Solid Tumors July 15, 2026
